News

IntroductionAccording to Mordor Intelligence, the transthyretin amyloidosis treatment market size is expected to reach USD 7.05 billion in 2026 and is forecast to…

The cross-border transfer of machine learning models based on the International Classification of Diseases, 10th revision (ICD-10) for the identification of rare…

AbstractBackgroundTransthyretin amyloid cardiomyopathy (ATTR-CM) causes heart failure with substantial morbidity, mortality, and healthcare utilization. ATTRibute-…

There are substantial delays from the time of incident heart failure to a diagnosis of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), according to a new…

AccurKardia Granted Patent for AI-Driven ECG Detection of Cardiac AmyloidosisPatent establishes IP across all major amyloidosis subtypes and transforms the standard…

Potential antibody therapies from AstraZeneca and Regeneron for light chain (AL) amyloidosis had new data at ASCO, raising the prospect of new treatments for the…

AbstractWild-type transthyretin amyloid (ATTRwt) amyloidosis is a systemic, progressive disease that often affects older adults and is characterized by ATTRwt…

Cardiac amyloidosis is an increasingly recognized infiltrative cardiomyopathy characterized by extracellular deposition of misfolded amyloid fibrils within the…

AbstractBackground: Acoramidis, an oral transthyretin stabilizer that achieves near-complete (≥90%) transthyretin stabilization, demonstrated significant clinical…

AbstractCardiac amyloidosis (CA) is a progressive infiltrative cardiomyopathy most commonly caused by transthyretin (ATTR) or immunoglobulin light chain (AL)…